Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Shionogi is acquiring CNS biopharmaceutical company IntraBio for an upfront consideration of $2B. Ono Pharmaceutical entered exclusive license agreement with Biohaven to develop and commercialize Biohaven’s IgG degrader portfolio.</li>
<li>Celltrion launched first Xolair biosimilar in the U.S. at 15% discount to the original product. Hanmi Pharmaceutical received domestic marketing approval for Eppe (Epeglenatide), a new GLP-1 class obesity drug.</li>
<li>CSL is mutually terminating the supply agreement with Terumo and is transitioning to Haemonetics platform. The company stuck new drug development deal with Alentis Therapeutics.</li>
</ul>


Shionogi is acquiring CNS biopharmaceutical company IntraBio for an upfront consideration of $2B. Ono Pharmaceutical entered exclusive license agreement with Biohaven to develop and commercialize Biohaven’s IgG degrader portfolio.
Celltrion launched first Xolair biosimilar in the U.S. at 15% discount to the original product. Hanmi Pharmaceutical received domestic marketing approval for Eppe (Epeglenatide), a new GLP-1 class obesity drug.
CSL is mutually terminating the supply agreement with Terumo and is transitioning to Haemonetics platform. The company stuck new drug development deal with Alentis Therapeutics.


APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL

Global Equities, Multi-Asset PM, Dantes Outlook

Damanick Dantes, CMT

Global Equities, Multi-Asset PM

Dantes Outlook

We invest over a full market cycle, using multi-asset portfolios tailored to each global client, from individuals to family offices.

Built to Endure

Cross Asset Strategy

<ul>
<li>The <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX 200 (AS51 INDEX)</a> appears oversold vs. world equities, but has not sustained upside momentum to warrant a broad allocation. Although dividends are nice over the long run.</li>
<li>We constructed a 12-name basket that can scale as the index trend improves. The basket holds a mix of cyclical and defensive stocks.</li>
<li>A narrower rate differential with the US may help, but significantly less so for USD-investors like us. The bar is high for Aussie equities, so we prefer stock selection.</li>
</ul>


The S&amp;P/ASX 200 (AS51 INDEX) appears oversold vs. world equities, but has not sustained upside momentum to warrant a broad allocation. Although dividends are nice over the long run.
We constructed a 12-name basket that can scale as the index trend improves. The basket holds a mix of cyclical and defensive stocks.
A narrower rate differential with the US may help, but significantly less so for USD-investors like us. The bar is high for Aussie equities, so we prefer stock selection.


Australia: Value Down Under Awaiting Confirmation. Here’s a Stock Basket That Scales

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Australia's ASIC releases the aggregated short position data four business days after the reporting day. Data in this insight is up to 24th August, published on the 28th August.</li>
<li>The largest industry net increase in the past week was A$0.4bn into "Biotechnology"; the largest industry net decrease was A$0.2bn out of "Banks". Net shorts increased A$1.2bn week-on-week.</li>
<li>Companies mentioned in this regular weekly report include: <a href="https://www.smartkarma.com/entities/csl-ltd" target="_blank" data-smartkarma-citation="entities:917:1" rel="noopener">CSL Ltd (CSL AU)</a>, <a href="https://www.smartkarma.com/entities/pls-group-limited" target="_blank" data-smartkarma-citation="entities:7460:1" rel="noopener">PLS Group (PLS AU)</a>, <a href="https://www.smartkarma.com/entities/evolution-mining-ltd" target="_blank" data-smartkarma-citation="entities:18363:1" rel="noopener">Evolution Mining (EVN AU)</a>, <a href="https://www.smartkarma.com/entities/stockland" target="_blank" data-smartkarma-citation="entities:661:1" rel="noopener">Stockland (SGP AU)</a>, and <a href="https://www.smartkarma.com/entities/pro-medicus-ltd" target="_blank" data-smartkarma-citation="entities:13516:1" rel="noopener">Pro Medicus Ltd (PME AU)</a>.</li>
</ul>


Australia's ASIC releases the aggregated short position data four business days after the reporting day. Data in this insight is up to 24th August, published on the 28th August.
The largest industry net increase in the past week was A$0.4bn into "Biotechnology"; the largest industry net decrease was A$0.2bn out of "Banks". Net shorts increased A$1.2bn week-on-week.
Companies mentioned in this regular weekly report include: CSL Ltd (CSL AU), PLS Group (PLS AU), Evolution Mining (EVN AU), Stockland (SGP AU), and Pro Medicus Ltd (PME AU).


Aussie Shorts [24 Aug 2026]: CSL, PLS Group, Evolution Mining, Stockland, Pro Medicus

Financial News, Analysis and Data, FNArena

FNArena

Financial News, Analysis and Data

Online financial media company focused on Australian equities, with a global perspective

Equity Bottom-Up

<ul><li>CSL's FY26 result and FY27 guidance suggest a recovery may be underway following a long run of downgrades.</li><li> CSL&rsquo;s FY26 result beat low expectations Slowing declines in the second half from the first imply positive trends More constructive commentary around Ig markets the highlight of FY27 guidance The worst appears over, but most analysts remain cautious</li></ul>

CSL's FY26 result and FY27 guidance suggest a recovery may be underway following a long run of downgrades. CSL&rsquo;s FY26 result beat low expectations Slowing declines in the second half from the first imply positive trends More constructive commentary around Ig markets the highlight of FY27 guidance The worst appears over, but most analysts remain cautious

CSL's FY26 Suggests The Downtrend Is Done

<ul>
<li>
<a href="https://www.smartkarma.com/entities/csl-ltd" target="_blank" data-smartkarma-citation="entities:917:1" rel="noopener">CSL Ltd (CSL AU)</a> announced FY26 result, reporting revenue of $15.8B, down 1% YoY. After one-off restructuring costs and impairments, the company reported a net loss of $2.6B.   </li>
<li>In FY27, CSL expects underlying NPAT growth of 5% on flat revenue. NPAT outlook exceeds market consensus expectations, thereby cementing CSL’s core operational rebound.</li>
<li>Despite CSL Vifor headwinds (revenue decline of 25% YoY mainly due to generic competition in iron products), Behring and Seqirus are expected to return to growth path.</li>
</ul>



CSL Ltd (CSL AU) announced FY26 result, reporting revenue of $15.8B, down 1% YoY. After one-off restructuring costs and impairments, the company reported a net loss of $2.6B.   
In FY27, CSL expects underlying NPAT growth of 5% on flat revenue. NPAT outlook exceeds market consensus expectations, thereby cementing CSL’s core operational rebound.
Despite CSL Vifor headwinds (revenue decline of 25% YoY mainly due to generic competition in iron products), Behring and Seqirus are expected to return to growth path.


CSL Ltd (CSL AU): Initial Sign of Recovery or a Dead Cat Bounce?

Australia

CSL Limited develops, manufactures and markets human pharmaceutical and diagnostic products derived from human plasma. The Company's products include pediatric and adult vaccines, infection, pain medicine, skin disorder remedies, antivenoms, anticoagulants, and immunoglobulins.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CSL Ltd (CSL AU)

APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL

Shionogi is acquiring IntraBio for $2B. Ono stuck inlicensing deal with Biohaven. Hanmi’s obesity drug got approval in Korea. CSL terminates supply...

Tina Banerjee

Australia: Value Down Under Awaiting Confirmation. Here’s a Stock Basket That Scales

Australian shares have lagged for a while, but we see opportunity in a basket of trending stocks. We can scale up if the index improves, while...

Damanick Dantes, CMT

Aussie Shorts [24 Aug 2026]: CSL, PLS Group, Evolution Mining, Stockland, Pro Medicus

Net shorts increased A$1.2bn week-on-week. Companies mentioned in this regular weekly include: CSL, PLS, Evolution Mining, Stockland, & Pro Medicus

David Blennerhassett

CSL's FY26 Suggests The Downtrend Is Done

CSL's FY26 result and FY27 guidance suggest a recovery may be underway following a long run of downgrades. CSL’s FY26 result beat low...

FNArena

CSL Ltd (CSL AU): Initial Sign of Recovery or a Dead Cat Bounce?

CSL announced FY26 result, in-line with updated guidance. The company expects 5% NPAT growth on flat revenue in FY27, thereby cementing operational...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)